explore -WSS

explore

author：hotspot 2025-09-28 08:53:27 - browse：333

Kara Coluccio, a managing partner at Perspective Group poses for a portrait. -- health coverage from STAT — Kara Coluccio, a managing partner at Perspective Group, says the job market for biotech executives has gotten much tighter. Jessica Rinaldi/Globe Staff

When Crystal Shih Byers left her job at Novartis in 2020, she was excited to make the leap into a smaller startup.

Byers had spent almost nine years at Novartis, most recently helping lead a group that worked on gene therapy. But pharmaceutical companies are large and complex, and she craved more immediate impact. “I was looking for a place where I could be in the room,” she says. She wanted more autonomy, and to feel like her work would reach patients sooner.

At the time, biotech startups were rolling in cash and seeking to capture some of the magic that had fueled Moderna’s meteoric rise. They handed out lots of logo-embossed swag. “Investors were putting a lot of money into stupid science,” Byers says. “There were a lot of companies that lasted for a lot longer than I thought they would on very little data.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Study points to new risk in gene therapy death of Terry Horgan

hotspot

WSS

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Eli Lilly, Pfizer, and others want in on the online prescription market

FDA clears AI tool for detecting skin cancer

Dewpoint Therapeutics lays off staff after losing partnerships

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Research misconduct: Proposed new rules face resistance

explore

explore

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Experts study whether long Covid risk adds up with each reinfection

United colonoscopy coverage change 'may cost lives,' doctors say

Parkinson’s finding may lead to tests and, someday, treatments

Trump demands the U.S. pay no more for drugs than other countries … again

The stability of $0 premiums in Medicare Advantage

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

6 solutions to address cancer drug shortages and others

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The biotech scorecard for Q4: 16 stock

entertainment

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

eGenesis tests gene

IVG is promising — but it won’t replace IVF quite yet

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Copay coupons to count toward deductibles, after Biden court move

Prior authorization will have to move faster under new Biden rule

focus

hotspot

knowledge

explore